Stocks

- A + A LONDON (Jan 20): European stocks fell on Thursday as cautious investors continued to assess how far and fast the US Federal Reserve will begin raising interest rates this year. Also keeping a lid on risk taking were the tech-laden US Nasdaq entering correction territory on Wednesday, a sell-off in bonds, still elevated crude oil prices and increased political tensions over Ukraine. But Chinese stocks were a bright spot after the country cut benchmark mortgage reference rates to ease pressure on its property sector. The STOXX index of 600 European companies was down 0.17% at 480 points, below its life-time high of 495.46 points hit in the first week of trading this year. Blue-chip indexes in Frankfurt, Paris and London were all lower. Gains in Asia helped to counter the pullback in Europe to keep the MSCI all country stock index in positive territory, up 0.16% at 728 points, but still down about 3.8% so far this year. "There is a tonne of caution now," … [Read more...] about Stocks slip in Europe as investors refine Fed hike bets

For more than a decade, growth stocks have been the talk of Wall Street. Historically low lending rates have rolled out the red carpet for fast-paced companies and allowed them to borrow cheaply in order to hire, acquire, and innovate. But what you might not realize is that value stocks have actually outperformed growth stocks over the very long run. Since value stocks are profitable and time-tested, they're the perfect place for patient investors to put their money to work. Below are five value stocks that could make you richer in 2022. Image source: Getty Images. General Motors The days of General Motors ( NYSE:GM ) being just another stagnant auto stock are gone. The electrification of automobiles has placed a multi-decade growth opportunity on the company's doorstep, and it'll undoubtedly run with it. In June, General Motors announced plans to up its investments in electric vehicles (EVs), autonomous vehicles, and batteries to $35 billion by 2025 . The … [Read more...] about 5 Value Stocks That Can Make You Richer in 2022

Berkshire Hathaway ( NYSE:BRK.A ) ( NYSE:BRK.B ) CEO Warren Buffett is widely considered as one of the greatest investors of all time. One of Buffett's keys to success -- and a core lesson learned from his mentor Benjamin Graham -- has been to invest with a so-called "margin of safety." This concept centers on the idea of buying stocks trading a substantial discount relative to their intrinsic value. While the intrinsic value of a stock means different things to different investors, one of the common themes across the galaxy of definitions for this time-tested investing concept is to focus on companies with strong free cash flows, a solid balance sheet, and a growing dividend program. By taking this approach, investors can essentially ignore the inherent volatility in the market from year to year and simply let the company's strong fundamentals do the heavy lifting, so to speak. Which Berkshire Hathaway holdings -- a.k.a. Warren Buffett stocks -- are the best buys during … [Read more...] about 2 Best Warren Buffett Dividend Stocks to Buy Now

If you're looking for better-than-average dividend yields, there's a pharmaceutical stock you need to take a look at. At recent prices, AbbVie ( NYSE:ABBV ) offers a 4.1% dividend yield that's impossible to ignore. Over the past year, the average dividend-paying stock in the S&P 500 index delivered a lousy 1.3% yield. If the big yield AbbVie offers seems a little too good to be true, it's because there's a catch. Image source: Getty Images. Why the above-average yield? In a nutshell, fear of declining sales for AbbVie's lead drug, Humira, is the reason AbbVie offers a huge dividend yield that is more than double the benchmark average. It's been 20 years since the FDA first approved this injectable drug for the treatment of rheumatoid arthritis. U.S. Humira sales contributed $4.6 billion to AbbVie's top line during the third quarter, so replacing lost revenue from this drug is going to be a major challenge. Biosimilar competition in the EU broke through the … [Read more...] about Is AbbVie a Good Dividend Stock to Buy Right Now?

Loading up on growth stocks while they're at bargain prices can lead to some great long-term returns for investors. And with many of these stocks falling in recent weeks, there are plenty of good deals available right now. Among the cheapest stocks to consider include Bristol Myers Squibb ( NYSE:BMY ) and Dell Technologies ( NYSE:DELL ) . Both are trading at low earnings multiples and still possess many growth opportunities, so now could be an optimal time to add these safe investments to your portfolio. Image source: Getty Images. 1. Bristol Myers Squibb Although Bristol Myers pays an incredibly attractive 3.6% dividend yield, which is well above the S&P 500 average of 1.3%, you shouldn't overlook the growth potential here. Acquisitions have helped the company expand its top line (sales of $42.5 billion in 2020 were more than double the $20.8 billion Bristol Myers reported just three years earlier) and its portfolio of drugs. In 2019, Bristol Myers … [Read more...] about 2 Absurdly Cheap Growth Stocks to Buy in December

Every major U.S. stock index has taken a step backward since the start of December. U.S. equities have reversed course this month because of inflationary pressures, the omicron variant, and year-end tax-loss harvesting. What's the best strategy to navigate this chaotic market? Dividend stocks are always worth owning as part of a well-rounded portfolio. Equities that dole out regular dividends to shareholders, after all, can smooth out the rough patches during volatile periods in the market. What's more, these types of stocks come with a built-in level of safety because of their attractiveness as passive income vehicles. Which dividend stocks are must-owns right now? The top pharma stocks Amgen ( NASDAQ:AMGN ) , Bristol Myers Squibb ( NYSE:BMY ) , and GlaxoSmithKline ( NYSE:GSK ) are all worth adding to your portfolio soon. Here's a look at the key features associated with each of these three rock-solid dividend plays . Image source: Getty Images. 1. … [Read more...] about 3 Must-Own Dividend Stocks in This Chaotic Market

What happened Shares of Eli Lilly ( NYSE:LLY ) were jumping 8.3% as of 11:48 a.m. ET on Wednesday. The big gain came after the drugmaker provided an update for investors. Lilly announced that it has initiated a rolling submission to the Food and Drug Administration for pirtobrutinib in treating mantle cell lymphoma. The company said that it's planning new phase 3 clinical studies evaluating tirzepatide in obesity outcomes, sleep apnea, and kidney disease. It also released new biomarker data showing positive efficacy for donanemab in treating Alzheimer's disease. Investors were most excited, though, about Lilly's updated guidance. The company looks for full-year 2021 revenue to be between $28 billion and $28.3 billion, with adjusted earnings per share (EPS) between $8.15 and $8.20. Both ranges are well above consensus estimates. Lilly also projects 2022 revenue will be between $27.8 billion and $28.3 billion with adjusted (EPS) between $8.50 and $8.65. This outlook is also … [Read more...] about Why Eli Lilly Stock Is Jumping Today

There's a common expression in the investing community, which goes as follows: "It's a market of stocks, not a stock market." This essentially means that even with the financial markets at or near all-time highs as they are now, not all stocks have fared well. Pharma stock Amgen ( NASDAQ:AMGN ) is a perfect example. At its current share price of $204, the stock is just a touch above its 52-week low and a whopping 26% below its 52-week high. Let's look at whether you should interpret this recent poor stock performance as a buying opportunity or a sign to steer clear of Amgen. Image source: Getty Images. A solid third-quarter performance Amgen reported $6.7 billion in revenue during the third quarter, which equates to a 4.4% growth rate against the year-ago period. What led to Amgen's respectable performance? Given Amgen's diversified portfolio of more than two dozen drugs, there were quite a few moving parts affecting growth in the quarter. Legacy medications such … [Read more...] about Should You Buy This Giant Biotech Stock?

Stocks rarely go straight up. When they do, the uncommon occurrence is called a "parabolic move." In stock terminology, such as move is defined by a sudden and dramatic increase in buying volume, thereby causing the company's share price to rapidly rise in a manner that resembles a parabola. Oddly enough, this phenomenon has happened on a far more regular basis in 2021 than at any other time in the history of the U.S. stock market. The most recent examples are the explosive upward moves by shares of Donald Trump's social media-associated stocks, Digital World Acquisition ( NASDAQ:DWAC ) and Phunware ( NASDAQ:PHUN ) . Last week, Digital World Acquisition's shares rose by as much as 1,500%. Phunware's shares, for their part, posted a jaw-dropping intraday high of over 2,000% during a single trading session last week. This week, it might be biotech 's turn at the parabolic-move game. Shares of Aurinia Pharmaceuticals ( NASDAQ:AUPH ) and Ocugen ( NASDAQ:OCGN … [Read more...] about 2 Biotech Stocks That Could Go Parabolic This Week

The Dow Jones Industrial Average is an index made up of 30 of the largest and most influential companies on U.S. stock exchanges. The index has historically returned around 7.5% each year, so being up over 15% makes 2021 a year to celebrate. Not every stock in the Dow Jones has performed well. The three stocks we'll discuss are all down and have been since the beginning of 2021, despite the index being up so much. We'll look at each one to determine whether they represent an opportunity or are down for a good reason. 1. Amgen Biotech company Amgen ( NASDAQ:AMGN ) has been down about 7% since the beginning of 2021. The company develops and sells drugs aimed at inflammation, cancer, bone health, heart disease, and more. Image source: Getty Images. When a company invents a successful drug, its formula is patented, protecting it from direct competition for many years. Medications can cost millions of dollars to research and develop but can fail when tested in trials. A … [Read more...] about Is It Time to Buy the Dow’s 3 Worst Performing Stocks This Year?